We are pleased to announce that Ricki A. Chase will join Lachman Consultants as a Director in the Compliance Practice, effective June 20, 2016.
Ricki Chase comes to Lachman Consultants after an impressive 16-year career, culminating as Director, Investigations Branch at the U.S. Food and Drug Administration where she was responsible for all operations of the Investigations Branch, including inspections, investigations, sample collections, consumer complaints, import operations, and emergency response programs. Ms. Chase is an expert in implementation of Food and Drug Law, Compliance Law, as well as Current Good Manufacturing Practice enforcement. She delivers leadership in all regulated program areas, including Pharmaceuticals, Medical Devices, Biomonitoring, Veterinary Medicine, Biologics, and Imports.
Ms. Chase received her Masters of Science in Biology from the University of Texas at Arlington and began her career as an Inspector in the Texas Department of Health. She transitioned to the U.S. FDA, and prior to her appointment as Director, Investigations Branch, served as Supervisory Investigator, Medical Device Specialist, after starting as an Investigator. While at FDA, she received a number of recognitions and awards for her outstanding contributions to the Agency. In addition, Ms. Chase is a frequent industry association speaker and guest lecturer.
On behalf of Lachman Consultants, we welcome Ricki for a successful and exciting career at our firm.
For more than 30 years, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available. Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutions based on the integration of scientific principles, evolving regulatory expectations, and technology.
